Pharma Sctors

Natco Pharma share price rises 5% on rating update; check key details here

Natco Pharma, in a regulatory filing, has informed the exchanges that the credit rating agency ICRA Limited has reaffirmed and assigned credit ratings for Natco Pharma's various debt instruments.

People should get proper remedy against pharma firms' malpractices: SC

The Supreme Court on Tuesday said procedures under the uniform code for pharmaceutical marketing should be so strong that any consumer who is cheated should have access and proper remedy against unethical practices. A bench of justices Vikram Nath and Sandeep Mehta observed there should be appropriate measures where the consumers have a convenient mechanism for lodging their complaints and ensuring that action is taken against erring companies. The top court was hearing a plea seeking that the uniform code of pharmaceutical marketing practices should curb alleged unethical practices of pharma firms. Additional Solicitor General K M Nataraj, appearing for the Centre, said the government has introduced several policies for the purpose of either restricting the pricing of medicines and to regulate such activities. He referred to the Uniform Code for Pharmaceuticals Marketing Practices (UCPMP), 2024, which prohibits pharma companies from offering gifts and travel facilities to healthca

NPPA extends knee implant price ceiling by one year till November 2026

The NPPA has extended the knee implant price cap despite industry requests to remove or relax it, citing rising costs and innovation needs, as the regulator prioritises affordability for patients

Risdiplam generic drug case: SC rejects Roche plea against Natco pharma

The Supreme Court upheld Delhi HC's interim order allowing Natco Pharma to manufacture and sell a generic version of Roche's spinal muscular atrophy drug Risdiplam

India's pharma regulatory failures point to a deeper structural flaw

These are not independent, random occurrences. They are all pointers to a larger, more fundamental issue

Do kids even need cough syrups? Doctors say they may do more harm than good

The recent child deaths in MP and Rajasthan have reignited debate on whether cough syrups are safe or even effective for kids or are they a needless and risky habit?

What is the toxic DEG found in Coldrif cough syrup: All you need to know

DEG contamination in Coldrif cough syrup from Tamil Nadu has triggered state bans and a national probe amid fears of child deaths linked to toxic medicines

Dr Reddy's shares fall as USFDA flags Hyderabad plant with 5 observations

Dr Reddy's shares fell on Monday after the USFDA issued a Form 483 with five observations at its Hyderabad plant inspection

Biocon shares slip 3% as Q1 results miss estimates; should you sell?

Biocon shares fell 3 per cent after it reported a 95.2 per cent decline in net profit in Q1FY26

Nifty Pharma down 1.5%: Granules, Biocon lead with over 2% fall; Here's why

Pharma stocks fell after Trump said tariffs will be imposed within a week, rising up to 250 per cent in 12-18 months

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Trump on Wednesday called India's tariffs on US exports among the highest in the world, with the most strenuous non-monetary trade barriers of any country, in a post on Truth Social

Shivam Enterprise Pharma Division Launches New Range of Capsules and Tablets Section Under the Visionary Leadership of Mr. Sahil Diwan

New pharma section unveiled by Sahil Diwan

Gland Pharma shares rise on GMP nod for Telangana manufacturing unit

Gland Pharma shares rose 2 per cent after it received a GMP certification from the Danish Medicines Agency for its Telangana plant

Are generic medicines as good as branded ones? Here's what you should know

Are cheaper generic medicines really as good as expensive branded ones? Here's what doctors and pharma experts say about quality, safety, and trust

TPG acquires 35% in SCHOTT Poonawalla, SII retains minority stake

SCHOTT Pharma keeps 50% stake in Indian JV as TPG joins with Novo Holdings to support global pharma supply chain growth; deal expected to close in H1 2025

US pharma tariffs would raise US drug costs by $51 bn annually: Report

Pharmaceutical products have long been spared from trade wars due to the potential harms, but he has repeatedly threatened a 25 per cent tariff on pharmaceutical imports

Here's why Zydus Lifesciences share price popped 3% in trade on March 19

The rise in the Zydus Lifesciences shares came after the company received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg

Glenmark recalls 1.5 million bottles of ADHD medication in US: USFDA

Glenmark Pharmaceuticals is recalling close to 15 lakh bottles of a generic medication used in the treatment of attention deficit hyperactivity disorder in the US market, according to the US health regulator. Glenmark Pharmaceuticals Inc, USA, a subsidiary of the Mumbai-based drug maker, is recalling around 14.76 lakh bottles of Atomoxetine Capsules in multiple strengths. The company is recalling the affected lot due to "CGMP Deviations", the US Food and Drug Administration (USFDA) said in its latest Enforcement Report. The recall is due to "presence of N-Nitroso Atomoxetine impurity above the FDA recommended limit," it added. New Jersey-based Glenmark Pharmaceuticals Inc, USA is recalling the made-in-India product in strengths ranging from 10 mg to 100 mg, USFDA stated. The company initiated the Class II recall on January 29 this year. As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medic

Distributed manufacturing may become the future trend: Pharma Inc

Volumes need to be high to justify relocation of manufacturing; strategic decisions cannot be based on current tariff structure

What products and services may see their prices change in Budget 2025?

The Finance Minister is expected to prioritise economic growth, domestic manufacturing, and offer relief to consumers in the upcoming budget to address inflation, fiscal consolidation, and job creatio